相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Interval Change in Diffusion and Perfusion MRI Parameters for the Assessment of Pseudoprogression in Cerebral Metastases Treated With Stereotactic Radiation
James R. Knitter et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Multiparametric MRI for Differentiation of Radiation Necrosis From Recurrent Tumor in Patients With Treated Glioblastoma
Kambiz Nael et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases
Surabhi Ranjan et al.
BMC CANCER (2018)
Retrospective study of nivolumab for patients with recurrent high grade gliomas
Megan Mantica et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
K. Ina Ly et al.
SCIENTIFIC REPORTS (2018)
Glioblastoma under Siege: An Overview of Current Therapeutic Strategies
Mayra Paolillo et al.
BRAIN SCIENCES (2018)
RANDOMIZED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: CHECKMATE 143
D. A. Reardona et al.
NEURO-ONCOLOGY (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Benjamin M. Ellingson et al.
NEUROTHERAPEUTICS (2017)
The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis
Song Xue et al.
SCIENTIFIC REPORTS (2017)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Eric Bouffet et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Deborah T. Blumenthal et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
Tanner M. Johanns et al.
CANCER DISCOVERY (2016)
Safety of pembrolizumab in combination with bevacizumab in recurrent glioblastoma (rGBM).
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada et al.
LANCET ONCOLOGY (2015)
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment
Jerrold L. Boxerman et al.
NEURO-ONCOLOGY (2015)
Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immunerelated Adverse Events
Jennifer J. Kwak et al.
RADIOGRAPHICS (2015)
Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction
Mark A. Socinski
SEMINARS IN ONCOLOGY (2015)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff et al.
NEURO-ONCOLOGY (2015)
Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma
Kathleen M. Schmainda et al.
NEURO-ONCOLOGY (2014)
Immunotherapy advances for glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2014)
Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metrics
Daniel Rodriguez Gutierrez et al.
NEURO-ONCOLOGY (2013)
Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications
Rajan Jain
NMR IN BIOMEDICINE (2013)
Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-weighted Imaging
Hee Ho Chu et al.
RADIOLOGY (2013)
Bayesian Hemodynamic Parameter Estimation by Bolus Tracking Perfusion Weighted Imaging
Timothe Boutelier et al.
IEEE TRANSACTIONS ON MEDICAL IMAGING (2012)
Tumor Immunotherapy Directed at PD-1
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Distinguishing Recurrent High-grade Gliomas from Radiation Injury: A Pilot Study Using Dynamic Contrast-enhanced MR Imaging
Sotirios Bisdas et al.
ACADEMIC RADIOLOGY (2011)
MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study
Matej Vrabec et al.
NEURORADIOLOGY (2011)
Distinguishing Glioma Recurrence from Treatment Effect After Radiochemotherapy and Immunotherapy
Isaac Yang et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Comparison of Dynamic Susceptibility-weighted Contrast-enhanced MR Methods: Recommendations for Measuring Relative Cerebral Blood Volume in Brain Tumors
Eric S. Paulson et al.
RADIOLOGY (2008)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme
L. Stenberg et al.
ACTA RADIOLOGICA (2006)
Rapid high-resolution T1 mapping by variable flip angles:: Accurate and precise measurements in the presence of radiofrequency field inhomogeneity
HLM Cheng et al.
MAGNETIC RESONANCE IN MEDICINE (2006)
Apparent diffusion coefficient of human brain tumors at MR imaging
F Yamasaki et al.
RADIOLOGY (2005)
Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors
TL Chenevert et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
